Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H.
Quach H, et al. Among authors: henderson r.
Br J Haematol. 2017 May;177(3):441-448. doi: 10.1111/bjh.14562. Epub 2017 Feb 15.
Br J Haematol. 2017.
PMID: 28197996
Free article.
Clinical Trial.